The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

During the first quarter, the Global Women’s Leadership portfolio lagged global developed market equities overall in the ...

Credit: Udo Salters/INSTARimages 2025 Native Son Awards celebrating Black Queer Excellence presented by Gilead Sciences honoring Colman Domingo, Paul Tazewell, Derrick Adams, Dr. David J. Johns, Sean ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

The company is now trading -4.54% away from its average analyst target price of $115.88 per share. The 26 analysts following ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.

Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...